November 02, 2018
A Virginia federal court shouldn't throw out multidistrict litigation accusing Merck & Co. Inc. and Glenmark Pharmaceuticals Inc. of manipulating the generic drug market to keep prices of the cholesterol medication Zetia high, buyers of the drug urged, claiming they can prove antitrust violations.
October 12, 2018
Merck & Co. Inc. and Glenmark Pharmaceuticals Inc. have asked a Virginia federal court to throw out three complaints in multidistrict litigation accusing them of entering into an illegal reverse-payment deal to keep a generic version of the cholesterol drug Zetia off the market.
July 30, 2018
More than a half-dozen law firms representing buyers of the cholesterol drug Zetia launched competing bids Friday to act as interim counsel for end payors for the drug in an antitrust MDL accusing Merck & Co. of orchestrating a pay-for-delay scheme to keep a generic version of the drug off the market.
July 03, 2018
A putative class of direct purchasers of the cholesterol drug Zetia asked a Virginia federal judge on Monday to consolidate their antitrust claims accusing Merck & Co. of orchestrating a pay-for-delay scheme to keep a generic version of the drug off the market.